147 related articles for article (PubMed ID: 34987644)
1. Driver mutations of intrahepatic cholangiocarcinoma shape clinically relevant genomic clusters with distinct molecular features and therapeutic vulnerabilities.
Wang XY; Zhu WW; Wang Z; Huang JB; Wang SH; Bai FM; Li TE; Zhu Y; Zhao J; Yang X; Lu L; Zhang JB; Jia HL; Dong QZ; Chen JH; Andersen JB; Ye D; Qin LX
Theranostics; 2022; 12(1):260-276. PubMed ID: 34987644
[No Abstract] [Full Text] [Related]
2. Clinicopathological, etiological and molecular characteristics of intrahepatic cholangiocarcinoma subtypes classified by mucin production and immunohistochemical features.
Chen Y; Liu X; Huang L; Chen L; Wang B
Expert Rev Mol Diagn; 2023 May; 23(5):445-456. PubMed ID: 37078255
[TBL] [Abstract][Full Text] [Related]
3. Clinically significant genomic alterations in the Chinese and Western patients with intrahepatic cholangiocarcinoma.
Xu S; Guo Y; Zeng Y; Song Z; Zhu X; Fan N; Zhang Z; Ren G; Zang Y; Rao W
BMC Cancer; 2021 Feb; 21(1):152. PubMed ID: 33579226
[TBL] [Abstract][Full Text] [Related]
4. Clinical, Genomic, and Transcriptomic Data Profiling of Biliary Tract Cancer Reveals Subtype-Specific Immune Signatures.
Mody K; Jain P; El-Refai SM; Azad NS; Zabransky DJ; Baretti M; Shroff RT; Kelley RK; El-Khouiery AB; Hockenberry AJ; Lau D; Lesinski GB; Yarchoan M
JCO Precis Oncol; 2022 Jun; 6():e2100510. PubMed ID: 35675577
[TBL] [Abstract][Full Text] [Related]
5. Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma.
Montal R; Sia D; Montironi C; Leow WQ; Esteban-Fabró R; Pinyol R; Torres-Martin M; Bassaganyas L; Moeini A; Peix J; Cabellos L; Maeda M; Villacorta-Martin C; Tabrizian P; Rodriguez-Carunchio L; Castellano G; Sempoux C; Minguez B; Pawlik TM; Labgaa I; Roberts LR; Sole M; Fiel MI; Thung S; Fuster J; Roayaie S; Villanueva A; Schwartz M; Llovet JM
J Hepatol; 2020 Aug; 73(2):315-327. PubMed ID: 32173382
[TBL] [Abstract][Full Text] [Related]
6. Charting co-mutation patterns associated with actionable drivers in intrahepatic cholangiocarcinoma.
Kendre G; Murugesan K; Brummer T; Segatto O; Saborowski A; Vogel A
J Hepatol; 2023 Mar; 78(3):614-626. PubMed ID: 36528236
[TBL] [Abstract][Full Text] [Related]
7. Molecular Profile of Intrahepatic Cholangiocarcinoma.
Andraus W; Tustumi F; de Meira Junior JD; Pinheiro RSN; Waisberg DR; Lopes LD; Arantes RM; Rocha Santos V; de Martino RB; Carneiro D'Albuquerque LA
Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203635
[TBL] [Abstract][Full Text] [Related]
8. Pan-tumor landscape of fibroblast growth factor receptor 1-4 genomic alterations.
Murugesan K; Necchi A; Burn TC; Gjoerup O; Greenstein R; Krook M; López JA; Montesion M; Nimeiri H; Parikh AR; Roychowdhury S; Schwemmers S; Silverman IM; Vogel A
ESMO Open; 2022 Dec; 7(6):100641. PubMed ID: 36462464
[TBL] [Abstract][Full Text] [Related]
9. Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles.
Farshidfar F; Zheng S; Gingras MC; Newton Y; Shih J; Robertson AG; Hinoue T; Hoadley KA; Gibb EA; Roszik J; Covington KR; Wu CC; Shinbrot E; Stransky N; Hegde A; Yang JD; Reznik E; Sadeghi S; Pedamallu CS; Ojesina AI; Hess JM; Auman JT; Rhie SK; Bowlby R; Borad MJ; ; Zhu AX; Stuart JM; Sander C; Akbani R; Cherniack AD; Deshpande V; Mounajjed T; Foo WC; Torbenson MS; Kleiner DE; Laird PW; Wheeler DA; McRee AJ; Bathe OF; Andersen JB; Bardeesy N; Roberts LR; Kwong LN
Cell Rep; 2017 Mar; 18(11):2780-2794. PubMed ID: 28297679
[TBL] [Abstract][Full Text] [Related]
10. Molecular Detection of
Zou Y; Zhu K; Pang Y; Han J; Zhang X; Jiang Z; Huang Y; Gu W; Ji Y
J Clin Transl Hepatol; 2023 Nov; 11(6):1355-1367. PubMed ID: 37719957
[TBL] [Abstract][Full Text] [Related]
11. Convergent genomic diversity and novel BCAA metabolism in intrahepatic cholangiocarcinoma.
Kitagawa A; Osawa T; Noda M; Kobayashi Y; Aki S; Nakano Y; Saito T; Shimizu D; Komatsu H; Sugaya M; Takahashi J; Kosai K; Takao S; Motomura Y; Sato K; Hu Q; Fujii A; Wakiyama H; Tobo T; Uchida H; Sugimachi K; Shibata K; Utsunomiya T; Kobayashi S; Ishii H; Hasegawa T; Masuda T; Matsui Y; Niida A; Soga T; Suzuki Y; Miyano S; Aburatani H; Doki Y; Eguchi H; Mori M; Nakayama KI; Shimamura T; Shibata T; Mimori K
Br J Cancer; 2023 Jun; 128(12):2206-2217. PubMed ID: 37076565
[TBL] [Abstract][Full Text] [Related]
12. Current challenges to underpinning the genetic basis for cholangiocarcinoma.
Cigliano A; Chen X; Calvisi DF
Expert Rev Gastroenterol Hepatol; 2021 May; 15(5):511-526. PubMed ID: 33888034
[TBL] [Abstract][Full Text] [Related]
13. In Vivo Modeling of Patient Genetic Heterogeneity Identifies New Ways to Target Cholangiocarcinoma.
Younger NT; Wilson ML; Martinez Lyons A; Jarman EJ; Meynert AM; Grimes GR; Gournopanos K; Waddell SH; Tennant PA; Wilson DH; Guest RV; Wigmore SJ; Acosta JC; Kendall TJ; Taylor MS; Sproul D; Mill P; Boulter L
Cancer Res; 2022 Apr; 82(8):1548-1559. PubMed ID: 35074757
[TBL] [Abstract][Full Text] [Related]
14. Intratumoral heterogeneity of intrahepatic cholangiocarcinoma.
Walter D; Döring C; Feldhahn M; Battke F; Hartmann S; Winkelmann R; Schneider M; Bankov K; Schnitzbauer A; Zeuzem S; Hansmann ML; Peveling-Oberhag J
Oncotarget; 2017 Feb; 8(9):14957-14968. PubMed ID: 28146430
[TBL] [Abstract][Full Text] [Related]
15. Immune checkpoint inhibitor-related molecular markers predict prognosis in extrahepatic cholangiocarcinoma.
Jin B; Wang Y; Zhang B; Xu H; Lu X; Sang X; Wang W; Mao Y; Chen P; Wang S; Qian Z; Wang Y; Du S
Cancer Med; 2023 Oct; 12(20):20470-20481. PubMed ID: 37814942
[TBL] [Abstract][Full Text] [Related]
16. Integrative analysis of multiple genomic data from intrahepatic cholangiocarcinoma organoids enables tumor subtyping.
Lee HS; Han DH; Cho K; Park SB; Kim C; Leem G; Jung DE; Kwon SS; Kim CH; Jo JH; Lee HW; Song SY; Park JY
Nat Commun; 2023 Jan; 14(1):237. PubMed ID: 36646721
[TBL] [Abstract][Full Text] [Related]
17. Molecular profile and its clinical impact of IDH1 mutated versus IDH1 wild type intrahepatic cholangiocarcinoma.
Rimini M; Fabregat-Franco C; Burgio V; Lonardi S; Niger M; Scartozzi M; Rapposelli IG; Aprile G; Ratti F; Pedica F; Verdaguer H; Rizzato M; Nichetti F; Lai E; Cappetta A; Macarulla T; Fassan M; De Braud F; Pretta A; Simionato F; De Cobelli F; Aldrighetti L; Fornaro L; Cascinu S; Casadei-Gardini A
Sci Rep; 2022 Nov; 12(1):18775. PubMed ID: 36335135
[TBL] [Abstract][Full Text] [Related]
18. Refining Classification of Cholangiocarcinoma Subtypes via Proteogenomic Integration Reveals New Therapeutic Prospects.
Cho SY; Hwang H; Kim YH; Yoo BC; Han N; Kong SY; Baek MJ; Kim KH; Lee MR; Park JG; Han SS; Lee WJ; Park C; Park JB; Kim JY; Park SJ; Woo SM
Gastroenterology; 2023 Jun; 164(7):1293-1309. PubMed ID: 36898552
[TBL] [Abstract][Full Text] [Related]
19. Oncogenic activation revealed by FGFR2 genetic alterations in intrahepatic cholangiocarcinomas.
Pu X; Qi L; Yan JW; Ai Z; Wu P; Yang F; Fu Y; Li X; Zhang M; Sun B; Yue S; Chen J
Cell Biosci; 2023 Nov; 13(1):208. PubMed ID: 37964396
[TBL] [Abstract][Full Text] [Related]
20. Recent Advances in Pathology of Intrahepatic Cholangiocarcinoma.
Choi JH; Thung SN
Cancers (Basel); 2024 Apr; 16(8):. PubMed ID: 38672619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
